| Year |
Citation |
Score |
| 2024 |
Fiskus W, Piel J, Collins MP, Hentemann M, Cuglievan B, Mill CP, Birdwell C, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, ... ... Bhalla KN, et al. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood. PMID 38437498 DOI: 10.1182/blood.2023022832 |
0.388 |
|
| 2024 |
Mill CP, Fiskus WC, DiNardo CD, Reville P, Davis JA, Birdwell CE, Das K, Hou H, Takahashi K, Flores L, Ruan X, Su X, Loghavi S, Khoury JD, Bhalla KN. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer Journal. 14: 25. PMID 38316746 DOI: 10.1038/s41408-024-00981-4 |
0.324 |
|
| 2023 |
Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, ... ... Bhalla KN, et al. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. PMID 38086946 DOI: 10.1038/s41375-023-02108-3 |
0.306 |
|
| 2023 |
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. PMID 37078252 DOI: 10.3324/haematol.2022.281915 |
0.318 |
|
| 2023 |
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, ... ... Bhalla KN, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer Journal. 13: 53. PMID 37055414 DOI: 10.1038/s41408-023-00826-6 |
0.319 |
|
| 2023 |
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, ... Bhalla KN, et al. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. PMID 36977823 DOI: 10.1038/s41375-023-01882-4 |
0.382 |
|
| 2022 |
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, ... Bhalla KN, et al. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. PMID 36151141 DOI: 10.1038/s41375-022-01707-w |
0.324 |
|
| 2022 |
Kannan S, Irwin ME, Herbrich SM, Cheng T, Patterson LL, Aitken MJL, Bhalla K, You MJ, Konopleva M, Zweidler-McKay PA, Chandra J. Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy. Antioxidants (Basel, Switzerland). 11. PMID 35453402 DOI: 10.3390/antiox11040717 |
0.353 |
|
| 2022 |
Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, ... ... Bhalla KN, et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer Journal. 12: 5. PMID 35017466 DOI: 10.1038/s41408-021-00603-3 |
0.329 |
|
| 2021 |
Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short NJ, Daver NG, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, ... ... Bhalla KN, et al. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood. PMID 34601571 DOI: 10.1182/blood.2021013156 |
0.379 |
|
| 2021 |
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, ... ... Bhalla KN, et al. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal. 11: 98. PMID 34016956 DOI: 10.1038/s41408-021-00487-3 |
0.395 |
|
| 2021 |
Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, ... ... Bhalla KN, et al. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. PMID 33654205 DOI: 10.1038/s41375-021-01181-w |
0.338 |
|
| 2020 |
Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 1531. PMID 32169966 DOI: 10.1158/1078-0432.Ccr-20-0412 |
0.381 |
|
| 2020 |
Saenz D, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury J, ... ... Bhalla KN, et al. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood. PMID 32068780 DOI: 10.1182/Blood.2019002922 |
0.414 |
|
| 2019 |
Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. PMID 31862959 DOI: 10.1038/S41375-019-0682-7 |
0.474 |
|
| 2019 |
Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, ... ... Bhalla K, et al. Targetable genetic alterations of () drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine. 11. PMID 31217338 DOI: 10.1126/Scitranslmed.Aav5599 |
0.395 |
|
| 2019 |
Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, ... ... Bhalla KN, et al. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. PMID 31023702 DOI: 10.1182/Blood.2018893982 |
0.463 |
|
| 2019 |
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, ... ... Bhalla KN, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal. 9: 4. PMID 30647404 DOI: 10.1038/S41408-018-0165-5 |
0.51 |
|
| 2019 |
Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Andreeff M, Garcia-Manero G, Jabbour E, Daver NG, Borthakur G, Pemmaraju N, Montalban-Bravo G, Benton CB, Short NJ, Bhalla KN, Cortes JE, et al. Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. Journal of Clinical Oncology. 37: 7034-7034. DOI: 10.1200/Jco.2019.37.15_Suppl.7034 |
0.303 |
|
| 2019 |
Karkhanis V, Fiskus W, Mill CP, Maiti A, Lara BH, Maher JV, Bhalla I, Shao N, Green MR, Khoury JD, Bhalla KN. Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL) Blood. 134: 3961-3961. DOI: 10.1182/Blood-2019-132041 |
0.511 |
|
| 2019 |
Fiskus W, Mill CP, Karkhanis V, Lara BH, Bose P, Masarova L, Kadia TM, Shao N, Bhalla I, Maher JV, Khoury JD, Sharma S, Manshouri T, Verstovsek S, Bhalla KN. Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells Blood. 134: 1274-1274. DOI: 10.1182/Blood-2019-130783 |
0.372 |
|
| 2019 |
Saenz DT, Fiskus WC, Manshouri T, Mill CP, Khoury JD, Verstovsek S, Bhalla KN. Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML Cancer Research. 79: 3836-3836. DOI: 10.1158/1538-7445.Am2019-3836 |
0.512 |
|
| 2019 |
Saenz DT, Fiskus WC, Manshouri T, Mill CP, Horrigan S, Soldi R, Khoury JD, Sharma S, Verstovesek S, Bhalla KN. Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor Cancer Research. 79: 3036-3036. DOI: 10.1158/1538-7445.Am2019-3036 |
0.419 |
|
| 2019 |
Fiskus WC, Maiti A, Saenz DT, Mill CP, Khoury JD, Bhalla KN. Abstract 1071: Targeted therapy evaluation in novel pre-clinical in vitro and in vivo models of Richter transformation Cancer Research. 79: 1071-1071. DOI: 10.1158/1538-7445.Am2019-1071 |
0.446 |
|
| 2019 |
Wang F, Morita K, DiNardo C, Patel K, MacBeth K, Wu B, Attar E, Liu G, Tossolini A, Frattini M, Matthews J, Little L, Gumbs C, Tippen S, Song X, ... ... Bhalla K, et al. Evolution of the AML Genome and Epigenome during IDH Inhibitor Therapy and their Association with Clinical Response and Resistance Clinical Lymphoma Myeloma and Leukemia. 19: S238-S239. DOI: 10.1016/J.Clml.2019.07.131 |
0.303 |
|
| 2019 |
Morita K, Wang F, Jahn K, Kuipers J, Yan Y, Matthews J, Little L, Gumbs C, Chen S, Zhang J, Song X, Thompson E, Patel K, Bueso-Ramos C, DiNardo C, ... ... Bhalla K, et al. Deconvolution of Clonal Heterogeneity in Acute Myeloid Leukemia using Single-Cell DNA Sequencing Clinical Lymphoma Myeloma and Leukemia. 19: S234. DOI: 10.1016/J.Clml.2019.07.121 |
0.307 |
|
| 2018 |
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, ... ... Bhalla KN, et al. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. PMID 30575820 DOI: 10.1038/S41375-018-0334-3 |
0.376 |
|
| 2018 |
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, ... ... Bhalla KN, et al. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. American Journal of Hematology. PMID 30328139 DOI: 10.1002/Ajh.25318 |
0.31 |
|
| 2018 |
DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G. Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes. Journal of Immunology (Baltimore, Md. : 1950). PMID 29752313 DOI: 10.4049/Jimmunol.1800101 |
0.303 |
|
| 2018 |
Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, et al. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia & Lymphoma. 1-12. PMID 29741984 DOI: 10.1080/10428194.2018.1464158 |
0.341 |
|
| 2018 |
Fiskus W, Mill CP, Soldi R, Han R, Saenz DT, Nowak AJ, Sun B, Saenz DN, DiNardo CD, Borthakur G, Kadia TM, Jin W, Ganesh T, Rao V, Khoury JD, ... ... Bhalla KN, et al. Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells Blood. 132: 3930-3930. DOI: 10.1182/Blood-2018-99-114198 |
0.469 |
|
| 2018 |
Mill CP, Cai T, Fiskus W, Borthakur G, Kornblau SM, Kadia TM, DiNardo CD, Nowak AJ, Saenz DT, Saenz DN, Sun B, Ganesh T, Jin W, Rao V, Khoury JD, ... ... Bhalla KN, et al. Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells Blood. 132: 1351-1351. DOI: 10.1182/Blood-2018-99-113976 |
0.392 |
|
| 2018 |
Saenz DT, Fiskus W, Manshouri T, Saenz DN, Soldi R, Sun B, Mill CP, Nowak AJ, Kornblau SM, Bose P, Kadia TM, DiNardo CD, Masarova L, Horrigan S, Khoury JD, ... ... Bhalla KN, et al. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis Blood. 132: 177-177. DOI: 10.1182/Blood-2018-177 |
0.39 |
|
| 2018 |
Mill CP, DiNardo CD, Fiskus W, Saenz DT, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Bhalla KN. Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1 Cancer Research. 78: 3884-3884. DOI: 10.1158/1538-7445.Am2018-3884 |
0.46 |
|
| 2017 |
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances. 1: 1312-1323. PMID 29296774 DOI: 10.1182/Bloodadvances.2017008227 |
0.328 |
|
| 2017 |
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, et al. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. American Journal of Hematology. PMID 29218851 DOI: 10.1002/Ajh.25000 |
0.35 |
|
| 2017 |
Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences. 18. PMID 28933735 DOI: 10.3390/Ijms18081618 |
0.307 |
|
| 2017 |
Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, ... ... Bhalla KN, et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. PMID 28663582 DOI: 10.1038/Leu.2017.207 |
0.532 |
|
| 2017 |
Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Research and Treatment. PMID 28623430 DOI: 10.1007/S10549-017-4310-9 |
0.34 |
|
| 2017 |
Promod ST, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, et al. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. PMID 28579617 DOI: 10.1038/Leu.2017.174 |
0.412 |
|
| 2017 |
Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. PMID 28322226 DOI: 10.1038/Leu.2017.77 |
0.424 |
|
| 2017 |
Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, ... ... Bhalla KN, et al. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia. PMID 28042144 DOI: 10.1038/Leu.2016.393 |
0.492 |
|
| 2017 |
Sun B, Fiskus W, Raina K, Qian Y, Crew A, Saenz DT, Mill CP, Nowak AJ, Saenz DN, Crews CM, Bhalla KN. Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells Blood. 130: 1265-1265. DOI: 10.1182/Blood.V130.Suppl_1.1265.1265 |
0.463 |
|
| 2017 |
Mill CP, DiNardo C, Fiskus WC, Saenz DT, Sun B, Nowak AJ, Kim M, Routbort M, Takahashi K, Bhalla KN. Abstract LB-081: Novel and effective RUNX1-targeted therapy for AML expressing RUNX1 mutation Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-081 |
0.445 |
|
| 2017 |
Saenz DT, Fiskus WC, Raina K, Manshouri T, Coleman KG, Qian Y, Crew AP, Shen A, Mill CP, Sun B, Kim M, Nowak AJ, Verstovsek S, Crews CM, Bhalla KN. Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells Cancer Research. 77: 5067-5067. DOI: 10.1158/1538-7445.Am2017-5067 |
0.466 |
|
| 2017 |
Saenz D, Fiskus W, Manshouri T, Mill C, Sun B, Verstovsek S, Bhalla K. BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Exert Potent Activity Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s)-AML Cells Clinical Lymphoma Myeloma and Leukemia. 17: S358. DOI: 10.1016/J.Clml.2017.07.189 |
0.389 |
|
| 2016 |
Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, et al. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. PMID 27927766 DOI: 10.3324/Haematol.2016.152710 |
0.373 |
|
| 2016 |
Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, ... Bhalla KN, et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. PMID 27677740 DOI: 10.1038/Leu.2016.260 |
0.525 |
|
| 2016 |
Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick A, Bhalla KN. SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress inducing agents. Cancer Research. PMID 27503926 DOI: 10.1158/0008-5472.Can-16-0126 |
0.395 |
|
| 2016 |
Bhalla KN, Fiskus W. NEDD8 and HDACs: promising cotargets in AML. Blood. 127: 2168-70. PMID 27151736 DOI: 10.1182/Blood-2016-02-699058 |
0.364 |
|
| 2016 |
Saenz DT, Fiskus W, Raina K, Manshouri T, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Mill CP, Sun B, Verstovsek S, Crews C, Bhalla KN. Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells Blood. 128: 747-747. DOI: 10.1182/Blood.V128.22.747.747 |
0.479 |
|
| 2016 |
Sun B, Fiskus W, Zhang L, Raina K, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Saenz DT, Mill CP, Wang M, Crews C, Bhalla KN. Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells Blood. 128: 1058-1058. DOI: 10.1182/Blood.V128.22.1058.1058 |
0.533 |
|
| 2016 |
Saenz DT, Fiskus WC, Manshouri T, Lu J, Qian Y, Raina K, Sun B, Krieger SS, Parmar S, Verstovsek S, Bhalla KN. Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells Cancer Research. 76: 4699-4699. DOI: 10.1158/1538-7445.Am2016-4699 |
0.519 |
|
| 2016 |
Bhalla K, Sun B, Fiskus W, Zhang L, Saenz D, Mill C, Wang M. Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells Clinical Lymphoma Myeloma and Leukemia. 16: S108-S109. DOI: 10.1016/J.Clml.2016.07.157 |
0.406 |
|
| 2016 |
Bhalla K, Saenz D, Fiskus W, Manshouri T, Sun B, Mill C, Verstovsek S. Superior Lethal Activity of Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) versus BET Protein Bromodomain Inhibitor (BETi) Against Post-Myeloprofilerative Neoplasm (MPN) Secondary AML Cells Clinical Lymphoma Myeloma and Leukemia. 16: S93-S94. DOI: 10.1016/J.Clml.2016.07.132 |
0.432 |
|
| 2015 |
Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. PMID 26254443 DOI: 10.1182/Blood-2015-04-639542 |
0.527 |
|
| 2015 |
Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S. Design, Synthesis and Biological Evaluation of a Series of anthracene-9, 10-dione dioxime ß-catenin Pathway Inhibitors. Journal of Medicinal Chemistry. PMID 26182238 DOI: 10.1021/Acs.Jmedchem.5B00460 |
0.345 |
|
| 2015 |
Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. PMID 26148704 DOI: 10.1038/Leu.2015.142 |
0.35 |
|
| 2015 |
Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 29: 1267-78. PMID 25482131 DOI: 10.1038/Leu.2014.340 |
0.403 |
|
| 2015 |
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, et al. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia Blood. 126: 564-564. DOI: 10.1182/Blood.V126.23.564.564 |
0.309 |
|
| 2015 |
Sun B, Fiskus W, Saenz DT, Krieger S, Zhang L, Parmar S, Wang M, Bhalla KN. BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells Blood. 126: 3704-3704. DOI: 10.1182/Blood.V126.23.3704.3704 |
0.538 |
|
| 2015 |
Saenz DT, Fiskus W, Manshouri T, Sun B, Krieger S, Parmar S, Verstovsek S, Bhalla KN. Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells Blood. 126: 1269-1269. DOI: 10.1182/Blood.V126.23.1269.1269 |
0.541 |
|
| 2015 |
Devaraj SGT, Shah B, Fiskus W, Sun B, Saha S, Pingali SR, Iyer SP, Sharma S, Bradner JE, Bhalla KN. Abstract 2623: Molecular mechanism of synergy between BET-protein bromodomain antagonist (BA) and pTEFb kinase inhibitor against human AML blast progenitor cells Cancer Research. 75: 2623-2623. DOI: 10.1158/1538-7445.Am2015-2623 |
0.409 |
|
| 2015 |
Sun B, Shah B, Fiskus W, Qi J, Devaraj SGT, Iyer SP, Sharma S, Bradner JE, Zu Y, Bhalla KN. Abstract 2612: BET-protein bromodomain antagonist-based combinations against ibrutinb-sensitive or resistant human Mantle Cell Lymphoma cells Cancer Research. 75: 2612-2612. DOI: 10.1158/1538-7445.Am2015-2612 |
0.411 |
|
| 2015 |
Sun B, Fiskus W, Saenz DT, Krieger S, Zhang L, Wang M, Bhalla KN. Pre-clinical activity of BET protein antagonist-based combinations against ibrutinib-sensitive or -resistant human Mantle Cell Lymphoma cells Clinical Lymphoma Myeloma and Leukemia. 15: S64. DOI: 10.1016/J.Clml.2015.07.129 |
0.348 |
|
| 2015 |
Fiskus W, Saenz DT, Krieger S, Bhalla KN. HEXIM1 induction mechanistically contributes to anti-AML activity of BET protein bromodomain antagonist Clinical Lymphoma Myeloma and Leukemia. 15: S10-S11. DOI: 10.1016/J.Clml.2015.07.025 |
0.335 |
|
| 2014 |
Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular Cancer Therapeutics. 13: 2315-27. PMID 25053825 DOI: 10.1158/1535-7163.Mct-14-0258 |
0.521 |
|
| 2014 |
Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 5: 5637-50. PMID 25026298 DOI: 10.18632/Oncotarget.2154 |
0.494 |
|
| 2014 |
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, et al. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Research and Treatment. 146: 145-52. PMID 24903226 DOI: 10.1007/S10549-014-3008-5 |
0.397 |
|
| 2014 |
Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 28: 2155-64. PMID 24699304 DOI: 10.1038/Leu.2014.119 |
0.465 |
|
| 2014 |
Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, ... ... Bhalla KN, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Research. 74: 2520-32. PMID 24599128 DOI: 10.1158/0008-5472.Can-13-2033 |
0.446 |
|
| 2014 |
Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular Cancer Therapeutics. 13: 1142-54. PMID 24435446 DOI: 10.1158/1535-7163.Mct-13-0770 |
0.513 |
|
| 2014 |
Tu Y, Hershman DL, Pellegrino CM, Andreopoulou E, Makower D, Fineberg S, Bhalla KN, Kalinsky K, Fehn K, Huang M, Alpaugh RK, Sparano JA. Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Journal of Clinical Oncology. 32: 598-598. DOI: 10.1200/Jco.2014.32.15_Suppl.598 |
0.359 |
|
| 2014 |
Sun B, Fiskus W, Shah B, Qi J, Devaraj SGT, Iyer SP, Sharma S, Bradner J, Zu Y, Bhalla KN. Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells Blood. 124: 918-918. DOI: 10.1182/Blood.V124.21.918.918 |
0.535 |
|
| 2014 |
Saha S, Fiskus W, Sharma S, Shah B, Rogojina AT, Devaraj SGT, Sun B, Leveque C, Zu Y, Iyer SP, Bhalla KN. Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD) Blood. 124: 618-618. DOI: 10.1182/Blood.V124.21.618.618 |
0.409 |
|
| 2014 |
Devaraj SGT, Fiskus W, Shah B, Sharma S, Qi J, Sun B, Saha S, Iyer SP, Zu Y, Bradner J, Bhalla KN. Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells Blood. 124: 3534-3534. DOI: 10.1182/Blood.V124.21.3534.3534 |
0.509 |
|
| 2014 |
Devaraj SGT, Fiskus W, Sharma S, Qi J, Shah B, Schaub LJ, Rodriguez M, Liu K, Iyer SP, Bradner JE, Bhalla KN. Abstract 3686: HEXIM1 induction exerts a mechanistic role and is a biomarker of lethal activity of BRD4 antagonist against human AML cells Cancer Research. 74: 3686-3686. DOI: 10.1158/1538-7445.Am2014-3686 |
0.531 |
|
| 2014 |
Rodriguez M, Fiskus W, Sharma S, Qi J, Schaub LJ, Shah B, Devaraj SGT, Liu K, Iyer S, Bradner JE, Bhalla KN. Abstract 1721: BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors Cancer Research. 74: 1721-1721. DOI: 10.1158/1538-7445.Am2014-1721 |
0.513 |
|
| 2013 |
Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica. 98: 1499-509. PMID 24091929 DOI: 10.3324/Haematol.2013.086348 |
0.36 |
|
| 2013 |
Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 33: 1341-52. PMID 23798029 DOI: 10.1002/Phar.1316 |
0.304 |
|
| 2013 |
DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. British Journal of Haematology. 162: 326-35. PMID 23701016 DOI: 10.1111/Bjh.12384 |
0.431 |
|
| 2013 |
Yang Y, Fiskus W, Yong B, Atadja P, Takahashi Y, Pandita TK, Wang HG, Bhalla KN. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proceedings of the National Academy of Sciences of the United States of America. 110: 6841-6. PMID 23569248 DOI: 10.1073/Pnas.1217692110 |
0.431 |
|
| 2013 |
Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Molecular Cancer Therapeutics. 12: 577-88. PMID 23445613 DOI: 10.1158/1535-7163.Mct-12-0862 |
0.474 |
|
| 2013 |
DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 27: 1628-36. PMID 23385375 DOI: 10.1038/Leu.2013.38 |
0.364 |
|
| 2013 |
Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 27: 907-13. PMID 23174881 DOI: 10.1038/Leu.2012.305 |
0.314 |
|
| 2013 |
Burns TA, Subathra M, Signorelli P, Choi Y, Yang X, Wang Y, Villani M, Bhalla K, Zhou D, Luberto C. Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene. Journal of Lipid Research. 54: 794-805. PMID 23160178 DOI: 10.1194/Jlr.M033985 |
0.454 |
|
| 2013 |
Bhalla KN, Fiskus W, Peth K. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human AML. Journal of Clinical Oncology. 31: 11107-11107. DOI: 10.1200/Jco.2013.31.15_Suppl.11107 |
0.521 |
|
| 2013 |
Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Jakkula LU, Rodriguez M, Devaraj S, Padmanabhan Iyer S, Bradner JE, Bhalla KN. BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells Blood. 122: 485-485. DOI: 10.1182/Blood.V122.21.485.485 |
0.528 |
|
| 2013 |
Rodriguez M, Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Devaraj S, Iyer SP, Bradner JE, Bhalla KN. Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD Blood. 122: 3821-3821. DOI: 10.1182/Blood.V122.21.3821.3821 |
0.543 |
|
| 2013 |
Saba NS, Ghias M, Manepalli R, Schorno K, Weir S, Austin C, Maddocks K, Byrd JC, Kambhampati S, Bhalla K, Wiestner A. Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia Blood. 122: 3819-3819. DOI: 10.1182/Blood.V122.21.3819.3819 |
0.424 |
|
| 2013 |
Valenta JA, Fiskus W, Manshouri T, Sharma S, Qi J, Schaub LJ, Shah B, Rodriguez M, Devaraj S, Iyer SP, Verstovsek S, Bradner JE, Bhalla KN. Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells Blood. 122: 2842-2842. DOI: 10.1182/Blood.V122.21.2842.2842 |
0.547 |
|
| 2013 |
Fiskus W, Balusu R, Peth K, Hembruff S, Abhyankar S, McGuirk J, Bhalla KN. Abstract 2034: Co-treatment with NPM1 antagonist and FLT3 inhibitor or pan-histone deacetylase inhibitor exerts superior efficacy against cultured and primary human AML cells co-expressing mutant NPM1 and FLT3-ITD. Cancer Research. 73: 2034-2034. DOI: 10.1158/1538-7445.Am2013-2034 |
0.516 |
|
| 2013 |
Fiskus WC, Rao R, Gupta SD, Chauhan L, Bhalla KN. Abstract 1011: Induction of ‘BRCAness’ by treatment with histone deacetylase inhibitors sensitizes human triple negative breast cancer cells to PARP inhibitor and cisplatinum. Cancer Research. 73: 1011-1011. DOI: 10.1158/1538-7445.Am2013-1011 |
0.497 |
|
| 2013 |
Shah B, Jakkula L, Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Rodriguez M, Devaraj SGT, Bradner JE, Bhalla KN. Abstract A124: Co-treatment with BRD4 antagonist and histone deacetylase inhibitor is synergistically lethal against Mantle Cell Lymphoma (MCL) cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A124 |
0.532 |
|
| 2012 |
Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 3: 1416-27. PMID 23232026 DOI: 10.18632/Oncotarget.724 |
0.484 |
|
| 2012 |
Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. HDAC inhibitors and chaperone function. Advances in Cancer Research. 116: 239-62. PMID 23088873 DOI: 10.1016/B978-0-12-394387-3.00007-0 |
0.396 |
|
| 2012 |
Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. Role of additional novel therapies in myeloproliferative neoplasms. Hematology/Oncology Clinics of North America. 26: 959-80. PMID 23009932 DOI: 10.1016/J.Hoc.2012.07.001 |
0.335 |
|
| 2012 |
Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6227-38. PMID 22932665 DOI: 10.1158/1078-0432.Ccr-12-0873 |
0.461 |
|
| 2012 |
Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Research and Treatment. 135: 433-44. PMID 22825030 DOI: 10.1007/S10549-012-2171-9 |
0.464 |
|
| 2012 |
Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Molecular Cancer Therapeutics. 11: 973-83. PMID 22367781 DOI: 10.1158/1535-7163.Mct-11-0979 |
0.505 |
|
| 2012 |
Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Research and Treatment. 132: 1063-72. PMID 22200869 DOI: 10.1007/S10549-011-1928-X |
0.379 |
|
| 2012 |
Arellano M, Winton E, Pan L, Lima L, Tighiouart M, Bhalla K, Heffner LT, Neely J, Hutcherson D, McLemore M, Langston A, Khoury HJ. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer. 118: 428-33. PMID 21717443 DOI: 10.1002/Cncr.26290 |
0.311 |
|
| 2012 |
Kambhampati S, Maddocks KJ, Rao R, Chauhan L, Gupta SD, Ganguly S, Reyes R, Aljitawi OS, Schorno K, Ford K, Dickman ED, Byrd JC, Bhalla KN. Effect of auranofin on oxidative and endoplasmic reticulum stress as well as anti-CLL activity with proteasome inhibitor. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E13568 |
0.387 |
|
| 2012 |
Bhalla KN, Fiskus W, Sharma S, Horrigan S, Mudunuru U, Reyes R, Abhyankar SH, McGuirk J, Aljitawi OS, Ganguly S. Anti-AML activity of a novel beta-catenin antagonist BC2059. Journal of Clinical Oncology. 30: 10605-10605. DOI: 10.1200/Jco.2012.30.15_Suppl.10605 |
0.447 |
|
| 2012 |
Fiskus W, Sharma S, Rao R, Balusu R, Venkannagari S, Ganguly S, Bearss D, Bhalla KN. Combined targeting of LSD1 (KDM1A) and histone deacetylases exerts superior efficacy against human AML. Journal of Clinical Oncology. 30: 10549-10549. DOI: 10.1200/Jco.2012.30.15_Suppl.10549 |
0.338 |
|
| 2012 |
Fiskus W, Sharma S, Abhyankar S, McGuirk J, Bearss DJ, Bhalla K. Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells Blood. 120: 868-868. DOI: 10.1182/Blood.V120.21.868.868 |
0.469 |
|
| 2012 |
Saba N, Shen M, Ghias M, Farooqui M, Austin C, Schorno K, Weir S, Bhalla K, Wiestner A. The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment Blood. 120: 865-865. DOI: 10.1182/Blood.V120.21.865.865 |
0.422 |
|
| 2012 |
Bhalla K, Fiskus W, Horrigan SK, Abhyankar S, McGuirk J, Sharma S. Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells Blood. 120: 287-287. DOI: 10.1182/Blood.V120.21.287.287 |
0.443 |
|
| 2012 |
Ha K, Fiskus W, Balusu R, Rao R, Venkannagari S, Bhalla KN. Abstract 4698: Inhibition of histone deacetylase (HDAC) 3 induces hyperacetylation and inhibition of nuclear heat shock protein (hsp) 90 leading to depletion of ATR and CHK1 with sensitization to DNA damage in breast and cervical cancer cells Cancer Research. 72: 4698-4698. DOI: 10.1158/1538-7445.Am2012-4698 |
0.437 |
|
| 2012 |
Manepalli RR, Chauhan L, Fiskus W, Balusu R, Nalabothula N, Venkannagari S, Ganguly S, Bhalla K. Abstract 2078: Treatment with auranofin induces oxidative and lethal endoplasmic reticulum (ER) stress exerting single agent activity against mantle cell lymphoma cells Cancer Research. 72: 2078-2078. DOI: 10.1158/1538-7445.Am2012-2078 |
0.481 |
|
| 2012 |
Fiskus WC, Sharma S, Rao R, Balusu R, Venkannagari S, Hembruff S, Abhyankar S, McGuirk J, Aljitawi O, Ganguly S, Bearss D, Bhalla KN. Abstract 1043: Combined targeting of chromatin modifying enzymes LSD1, histone deacetylases (HDACs) and EZH2 has superior efficacy against human acute myeloid leukemia cells. Cancer Research. 72: 1043-1043. DOI: 10.1158/1538-7445.Am2012-1043 |
0.534 |
|
| 2012 |
Bhalla K, Rao R, Sharma P, Gupta SD, Chauhan L, Stecklein S, Fiskus W. Abstract S3-7: Treatment with Histone Deacetylase Inhibitors Creates ‘BRCAness’ and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S3-7 |
0.459 |
|
| 2011 |
Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7347-58. PMID 21976548 DOI: 10.1158/1078-0432.Ccr-11-1541 |
0.413 |
|
| 2011 |
Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen L, Venkannagari S, Ha K, Abhyankar S, Williams C, McGuirk J, Khoury HJ, Ustun C, ... Bhalla KN, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood. 118: 3096-106. PMID 21719597 DOI: 10.1182/Blood-2010-09-309674 |
0.502 |
|
| 2011 |
Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, Nalabothula NR, Bhalla KN. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Molecular Cancer Therapeutics. 10: 1194-206. PMID 21566061 DOI: 10.1158/1535-7163.Mct-11-0094 |
0.424 |
|
| 2011 |
Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, Burchert A, Szulc Z, Bielawska A, Ozato K, Bhalla K, Liu K. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Research. 71: 2882-91. PMID 21487040 DOI: 10.1158/0008-5472.Can-10-2493 |
0.491 |
|
| 2011 |
Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. Journal of Immunology (Baltimore, Md. : 1950). 186: 3986-96. PMID 21368229 DOI: 10.4049/Jimmunol.1001101 |
0.364 |
|
| 2011 |
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 117: 1141-5. PMID 21098399 DOI: 10.1182/Blood-2010-03-277152 |
0.335 |
|
| 2011 |
Rao R, Maddocks K, Johnson AJ, Chauhan L, Kambhampati S, Ganguly S, Reyes R, Aljitawi OS, Schorno K, Ford K, Dickman E, Byrd JC, Bhalla KN. Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells Blood. 118: 929-929. DOI: 10.1182/Blood.V118.21.929.929 |
0.436 |
|
| 2011 |
Balusu R, Cox J, Hembruff S, Fiskus W, Rao R, Mudunuru U, Reyes R, Ganguly S, Abhyankar S, Male H, Fleming A, Williams CB, McGuirk J, Bhalla KN. Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists Blood. 118: 733-733. DOI: 10.1182/Blood.V118.21.733.733 |
0.521 |
|
| 2011 |
Fiskus W, Smith J, Mudunuru U, Hembruff S, Reyes R, Abhyankar S, McGuirk J, Aljitawi OS, Ganguly S, Horrigan SK, Sharma S, Bhalla KN. Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells Blood. 118: 65-65. DOI: 10.1182/Blood.V118.21.65.65 |
0.494 |
|
| 2011 |
Williams CB, Kambhampati S, Ganguly S, Aljitawi OS, Reyes R, Fleming A, Bhalla KN, Abhyankar S, McGuirk J. Results of a Phase I Open-Label Study of Decitabine in Combination with Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia, Blood. 118: 3610-3610. DOI: 10.1182/Blood.V118.21.3610.3610 |
0.359 |
|
| 2011 |
Fiskus W, Smith CC, Smith J, Wise SC, Lasater E, Damon LE, Salerno S, Fleming A, Reyes R, Ganguly S, Berger MS, Rutkoski TJ, McGuirk J, Shah N, Bhalla KN. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations Blood. 118: 2611-2611. DOI: 10.1182/Blood.V118.21.2611.2611 |
0.461 |
|
| 2011 |
Fiskus W, Sharma S, Rao R, Balusu R, Venkannagari S, Hembruff S, Ganguly S, Sotomayor EM, Tao J, Bearss DJ, Bhalla KN. Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells Blood. 118: 2429-2429. DOI: 10.1182/Blood.V118.21.2429.2429 |
0.531 |
|
| 2011 |
Balusu R, Fiskus W, Rao RM, Venkannagari S, Nalabothula N, Williams C, Abhyankar S, McGuirk J, Bhalla KN. Abstract 3539: Targeting levels and oligomerization of mutant nucleophosmin induces differentiation and loss of survival of human AML cells with mutant NPM1 Cancer Research. 71: 3539-3539. DOI: 10.1158/1538-7445.Am2011-3539 |
0.526 |
|
| 2011 |
Venkannagari S, Rao RM, Fiskus W, Balusu R, Ma H, Bhalla K. Abstract 2076: HSF1 inhibition accentuates the lethal activity of proteasome inhibitor in human pancreatic cancer cells Cancer Research. 71: 2076-2076. DOI: 10.1158/1538-7445.Am2011-2076 |
0.484 |
|
| 2011 |
Fiskus WC, Sharma S, Rao R, Balusu R, Tao J, Sotomayor E, Atadja P, Ganguly S, Bearss D, Bhalla KN. Abstract 2016: Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells Cancer Research. 71: 2016-2016. DOI: 10.1158/1538-7445.Am2011-2016 |
0.529 |
|
| 2011 |
Fiskus W, Smith J, Mudunuru U, Hembruff S, Reyes R, Abhyankar S, McGuirk J, Aljitawi O, Ganguly S, Horrigan S, Sharma S, Bhalla KN. Abstract C144: Treatment with β-catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C144 |
0.483 |
|
| 2010 |
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of Clinical Investigation. 120: 4569-82. PMID 21041953 DOI: 10.1172/Jci42869 |
0.483 |
|
| 2010 |
Choi JH, Li Y, Guo J, Pei L, Rauch TA, Kramer RS, Macmil SL, Wiley GB, Bennett LB, Schnabel JL, Taylor KH, Kim S, Xu D, Sreekumar A, Pfeifer GP, ... ... Bhalla KN, et al. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. Plos One. 5. PMID 20927367 DOI: 10.1371/Journal.Pone.0013020 |
0.314 |
|
| 2010 |
Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood. 116: 5306-15. PMID 20810927 DOI: 10.1182/Blood-2010-05-284414 |
0.492 |
|
| 2010 |
Rao R, Nalluri S, Fiskus W, Balusu R, Joshi A, Mudunuru U, Buckley KM, Robbins K, Ustun C, Reuther GW, Bhalla KN. Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells. Molecular Cancer Therapeutics. 9: 2232-42. PMID 20663926 DOI: 10.1158/1535-7163.Mct-10-0336 |
0.488 |
|
| 2010 |
Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4742-54. PMID 20647473 DOI: 10.1158/1078-0432.Ccr-10-0529 |
0.503 |
|
| 2010 |
Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood. 116: 2732-41. PMID 20566897 DOI: 10.1182/Blood-2009-11-256354 |
0.423 |
|
| 2010 |
Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, Ha K, Buckley KM, Balusu R, Coothankandaswamy V, Joshi A, Atadja P, Bhalla KN. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Molecular Cancer Therapeutics. 9: 942-52. PMID 20371724 DOI: 10.1158/1535-7163.Mct-09-0988 |
0.454 |
|
| 2010 |
Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 24: 699-705. PMID 20111068 DOI: 10.1038/Leu.2009.292 |
0.358 |
|
| 2010 |
Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 6: 19-35. PMID 20110775 DOI: 10.4161/Auto.6.1.10323 |
0.419 |
|
| 2010 |
DeAngelo DJ, Tefferi A, Mesa RA, Paley CS, Wadleigh M, Snyder D, Ondovik MS, Rine J, Bhalla KN. A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps283 |
0.376 |
|
| 2010 |
Ottmann OG, Fenaux P, Lübbert M, DeAngelo DJ, Garcia-Manero G, Bhalla KN, Sekeres MA, Lüdicke F, Weber HJ, Winiger IJ. A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps282 |
0.376 |
|
| 2010 |
Bhalla KN. Epigenetic Dysregulation in Lymphoid Malignancies Blood. 116. DOI: 10.1182/Blood.V116.21.Sci-29.Sci-29 |
0.411 |
|
| 2010 |
Fiskus W, Manepalli RR, Balusu R, Bhalla KN. Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F Blood. 116: 798-798. DOI: 10.1182/Blood.V116.21.798.798 |
0.48 |
|
| 2010 |
DeAngelo DJ, Tefferi A, Fiskus W, Mesa RA, Paley CS, Wadleigh M, Snyder DS, Begna K, Ondovik MS, Rine J, Bhalla KN. A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis Blood. 116: 630-630. DOI: 10.1182/Blood.V116.21.630.630 |
0.459 |
|
| 2010 |
Rao R, Fiskus W, Balusu R, Ma H, Bradner J, Tao J, Sotomayor EM, Bhalla KN. Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib Blood. 116: 2856-2856. DOI: 10.1182/Blood.V116.21.2856.2856 |
0.521 |
|
| 2010 |
Fiskus W, Rao R, Balusu R, Tao J, Sotomayor EM, Atadja P, Bhalla KN. Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells Blood. 116: 2488-2488. DOI: 10.1182/Blood.V116.21.2488.2488 |
0.493 |
|
| 2010 |
CoothanKandaswamy V, Chen J, Joshi A, Rao R, Fiskus W, Buckley KM, Nalluri S, Bhalla KN. Abstract 640: SIRT2 deacetylates peroxiredoxin and increases sensitivity to oxidative stress in human breast cancer cells Cancer Research. 70: 640-640. DOI: 10.1158/1538-7445.Am10-640 |
0.422 |
|
| 2010 |
Rao R, Nalluri S, Fiskus W, Mudunuru U, Bhalla KN. Abstract 4860: Pan-HDAC inhibitor treatment sensitizes breast cancer cells to autophagy inhibitor 2-phenylethynesulfonamide: Molecular mechanism Cancer Research. 70: 4860-4860. DOI: 10.1158/1538-7445.Am10-4860 |
0.478 |
|
| 2010 |
Bhalla KN. Abstract PL5-1: Targeting the nexus of heat shock and metabolic stress responses in cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-Pl5-1 |
0.421 |
|
| 2009 |
Kantarjian H, Giles F, Bhalla K, Pinilla J, Larson RA, Gattermann N, Ottmann OG, Gallagher NJ, Baccarani M, leCoutre P. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7029. PMID 27961402 DOI: 10.1200/Jco.2009.27.15_Suppl.7029 |
0.348 |
|
| 2009 |
Sessa C, Sharma SK, Britten CD, Vogelzang NJ, Bhalla KN, Mita MM, Pluard TJ, Stiegler P, Quadt C, Shapiro GI. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3532. PMID 27961345 DOI: 10.1200/Jco.2009.27.15_Suppl.3532 |
0.364 |
|
| 2009 |
Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine. 15: 1369-76. PMID 19966776 DOI: 10.1038/Nm.2059 |
0.464 |
|
| 2009 |
Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, ... Bhalla KN, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 114: 5024-33. PMID 19828702 DOI: 10.1182/Blood-2009-05-222133 |
0.499 |
|
| 2009 |
Robertson KD, Bhalla KN. Missteps in "tango" for epigenome targeting. Blood. 114: 2569-70. PMID 19779044 DOI: 10.1182/Blood-2009-07-231662 |
0.322 |
|
| 2009 |
Ustun C, DeRemer DL, Jillella AP, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. Expert Opinion On Investigational Drugs. 18: 1445-56. PMID 19671038 DOI: 10.1517/13543780903179278 |
0.374 |
|
| 2009 |
Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. British Journal of Haematology. 147: 97-101. PMID 19663825 DOI: 10.1111/J.1365-2141.2009.07837.X |
0.371 |
|
| 2009 |
Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 114: 2733-43. PMID 19638619 DOI: 10.1182/Blood-2009-03-213496 |
0.507 |
|
| 2009 |
Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biology & Therapy. 8: 1273-80. PMID 19440035 DOI: 10.4161/Cbt.8.13.8726 |
0.519 |
|
| 2009 |
Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy British Journal of Cancer. 100: 1523-1529. PMID 19401686 DOI: 10.1038/Sj.Bjc.6605066 |
0.35 |
|
| 2009 |
Buckley K, Fiskus W, Bhalla K. Activation of mTOR: A new mechanism "PIMed" Cancer Biology and Therapy. 8: 854-855. PMID 19363296 DOI: 10.4161/Cbt.8.9.8373 |
0.338 |
|
| 2009 |
Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biology & Therapy. 8: 939-50. PMID 19279403 DOI: 10.4161/Cbt.8.10.8213 |
0.46 |
|
| 2009 |
Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG. p53 acetylation is crucial for its transcription-independent proapoptotic functions. The Journal of Biological Chemistry. 284: 11171-83. PMID 19265193 DOI: 10.1074/Jbc.M809268200 |
0.418 |
|
| 2009 |
Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, ... Bhalla KN, et al. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 113: 4038-48. PMID 19074726 DOI: 10.1182/Blood-2008-08-176024 |
0.517 |
|
| 2009 |
Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology. 10: 92-100. PMID 19011628 DOI: 10.1038/Ni.1673 |
0.367 |
|
| 2009 |
Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leukemia Research. 33: 735-41. PMID 18986703 DOI: 10.1016/J.Leukres.2008.09.027 |
0.448 |
|
| 2009 |
Kantarjian HM, Jabbour E, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Wang J, Woodman RC, Baccarani M, le Coutre PD, Cortes J. Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data. Blood. 114: 3298-3298. DOI: 10.1182/Blood.V114.22.3298.3298 |
0.329 |
|
| 2009 |
DeAngelo DJ, Spencer A, Fischer T, Kindler T, Ottmann OG, Prince M, Giles FJ, Cortes J, Liu A, Parker K, Yan Y, Scott JW, Bhalla KN. Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis. Blood. 114: 2898-2898. DOI: 10.1182/Blood.V114.22.2898.2898 |
0.324 |
|
| 2009 |
Balusu R, Fiskus WC, Rao R, Buckley KM, Wang Y, Joshi A, Koul S, Jillella A, Ustun C, Sunay S, Khoury HJ, Bhalla KN. Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1. Blood. 114: 2656-2656. DOI: 10.1182/Blood.V114.22.2656.2656 |
0.524 |
|
| 2009 |
Fiskus WC, Buckley KM, Rao R, Wang Y, Joshi A, Chong DG, Jillella A, Ustun C, Atajada P, Quadt C, Bhalla KN. Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells. Blood. 114: 2651-2651. DOI: 10.1182/Blood.V114.22.2651.2651 |
0.523 |
|
| 2009 |
Kutlar A, Patel N, Ustun C, Natarajan K, Jillella A, Clair B, Kutlar F, Chandler R, Meiler SE, Bhalla KN. LBH589 (panobinostat): A Potential Novel Anti-Switching Therapy. Blood. 114: 2568-2568. DOI: 10.1182/Blood.V114.22.2568.2568 |
0.374 |
|
| 2009 |
Hu Y, Chen G, Jia Y, Zhang H, Huang P, Bhalla KN, Keating M, Garcia-Manero G. The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway. Blood. 114: 1739-1739. DOI: 10.1182/Blood.V114.22.1739.1739 |
0.444 |
|
| 2009 |
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D, Shou Y, Gallagher NJ, et al. Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. Blood. 114: 1129-1129. DOI: 10.1182/Blood.V114.22.1129.1129 |
0.311 |
|
| 2009 |
Upadhyay S, Fiskus WC, Rao R, Joshi A, Koul S, Balusu R, Mudunuru U, Buckley KM, Quadt C, Atadja P, Garcia‐Echeverria C, Bhalla KN. Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1 Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C196 |
0.443 |
|
| 2009 |
Rao R, Fiskus WC, Yang Y, Mudunuru U, Wang Y, Atadja P, Bhalla KN. Abstract B21: Targeting autophagy induced by pan‐HDAC inhibitor panobinostat and promoted by acetylated hsp70: A novel therapy for breast cancer Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B21 |
0.449 |
|
| 2009 |
Ramaswamy B, Bhalla K, Cohen B, Pellegrino C, Hershman D, Chuang E, Somlo G, Goetz M, Swaby R, Hopkins U, Christos P, Espinoza-Delgado I, Sparano J. Phase I-II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703. Cancer Research. 69: 404. DOI: 10.1158/0008-5472.Sabcs-404 |
0.37 |
|
| 2009 |
Samuel T, Fiskus W, Buser C, Bhalla K. A novel combination therapy with histone deacetylase inhibitor and Aurora kinase inhibitor for “triple negative” breast cancers. Cancer Research. 69: 401. DOI: 10.1158/0008-5472.Sabcs-401 |
0.438 |
|
| 2009 |
Swaby R, Wang M, Sparano J, Bhalla K, Meropol N, Falkson C, Pellegrino C, Klein P, Goldstein L, Sledge G. A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Research. 69: 5084-5084. DOI: 10.1158/0008-5472.Sabcs-09-5084 |
0.42 |
|
| 2009 |
Rao R, Nalluri S, Bhalla K. Anti-Breast Cancer Activity of a Novel Strategy of Targeting Autophagy Induced by Pan-HDAC Inhibitor and Acetylated Hsp70. Cancer Research. 69: 3124-3124. DOI: 10.1158/0008-5472.Sabcs-09-3124 |
0.459 |
|
| 2008 |
Natarajan K, Chen J, Kolhe R, Eaton K, Fiskus W, Rao R, Wang Y, Lee P, Atadja P, Bhalla KN. Depletion of HDAC7 and de-repression of Nur77: a mechanism for sensitivity of cutaneous lymphoma (CTCL) cells to pan- histone deacetylase inhibitor Panobinostat (LBH589). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14542. PMID 27950006 DOI: 10.1200/Jco.2008.26.15_Suppl.14542 |
0.449 |
|
| 2008 |
Kantarjian HM, Giles FJ, Hochhaus A, Bhalla KN, Ossenkoppele GJ, Gattermann N, Haque A, Gallagher N, Castagnetti F, le Coutre P. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7010. PMID 27949982 DOI: 10.1200/Jco.2008.26.15_Suppl.7010 |
0.346 |
|
| 2008 |
Jabbour E, Hochhaus A, le Coutre P, Rosti G, Bhalla KN, Haque A, Gallagher N, Giles FJ, Cortes JE, Kantarjian HM. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7063. PMID 27949632 DOI: 10.1200/Jco.2008.26.15_Suppl.7063 |
0.318 |
|
| 2008 |
Abruzzese E, Alimena G, le Coutre P, Bhalla KN, Ossenkoppele GJ, Haque A, Gallagher N, Kantarjian HM, Giles FJ. Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7055. PMID 27949592 DOI: 10.1200/Jco.2008.26.15_Suppl.7055 |
0.307 |
|
| 2008 |
Ustun C, Fiskus W, Wang Y, Rao R, Lee P, Kolhe R, Fernandez P, Jillella AP, Buser C, Bhalla KN. Co-treatment with aurora kinase inhibitor MK-0457 and pan-histone deacetylase inhibitor vorinostat: A novel targeted treatment for AML and CML. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11054. PMID 27947647 DOI: 10.1200/Jco.2008.26.15_Suppl.11054 |
0.459 |
|
| 2008 |
Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6106-15. PMID 18829489 DOI: 10.1158/1078-0432.Ccr-08-0721 |
0.399 |
|
| 2008 |
Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 112: 2896-905. PMID 18660379 DOI: 10.1182/Blood-2007-10-116319 |
0.483 |
|
| 2008 |
Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K. HDAC6 inhibition enhances 17-AAG mediated abrogation of hsp90 chaperone function in human leukemia cells Blood. 112: 1886-1893. PMID 18591380 DOI: 10.1182/Blood-2008-03-143644 |
0.416 |
|
| 2008 |
Jillella AP, Mandawat A, Fiskus W, Rao R, Wang Z, Wang Y, Atadja P, Fujii N, Peiper S, Bhalla KN. Effect of pan-histone deacetylase inhibitor panobinostat (LBH589) on CXCR4 levels and signaling and on anti-leukemia activity in combination with CXCR4 antagonists Journal of Clinical Oncology. 26: 14541-14541. DOI: 10.1200/Jco.2008.26.15_Suppl.14541 |
0.342 |
|
| 2008 |
Rao R, Fiskus W, Yang Y, Joshi R, Fernandez P, Lee P, Jillella A, Tao J, Atadja P, Sotomayor E, Bhalla KN. Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells Blood. 112: 887-887. DOI: 10.1182/Blood.V112.11.887.887 |
0.521 |
|
| 2008 |
Wang Y, Fiskus W, Natarajan K, Jillella A, Quadt C, Ataja P, Levine R, Bhalla KN. Co-Treatment with JAK2 Inhibitor TG101209 and Panobinostat or hsp90 Inhibitor AUY922 Attenuates Mutant JAK2-V617F Levels and Activity in Human Myeloproliferative Disorder Cells Blood. 112: 3739-3739. DOI: 10.1182/Blood.V112.11.3739.3739 |
0.511 |
|
| 2008 |
Fiskus W, Wang Y, Jillella A, Johnston P, Joshi R, Rao R, Sotomayor E, Tao J, Atadja P, Marqez V, Bhalla KN. Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells Blood. 112: 3622-3622. DOI: 10.1182/Blood.V112.11.3622.3622 |
0.507 |
|
| 2008 |
Fiskus W, Johnston P, Joshi R, Rao R, Ustun C, Jillella A, Atadja P, Hwang S, Redkar S, Bhalla KN. Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat. Blood. 112: 3355-3355. DOI: 10.1182/Blood.V112.11.3355.3355 |
0.506 |
|
| 2008 |
Kantarjian HM, Giles F, Bhalla KN, Larson RA, Gattermann N, Ottmann OG, Haque A, Gallagher NJ, Baccarani M, Coutre PDl. Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. Blood. 112: 3238-3238. DOI: 10.1182/Blood.V112.11.3238.3238 |
0.35 |
|
| 2008 |
Giles F, Coutre PDl, Bhalla KN, Ossenkoppele GJ, Alimena G, Haque A, Gallagher NJ, Kantarjian HM. Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study Blood. 112: 3234-3234. DOI: 10.1182/Blood.V112.11.3234.3234 |
0.349 |
|
| 2007 |
Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Research. 67: 10744-52. PMID 18006817 DOI: 10.1158/0008-5472.Can-07-3148 |
0.461 |
|
| 2007 |
Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, Bhalla K, Bai W. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nature Cell Biology. 9: 1253-62. PMID 17934453 DOI: 10.1038/Ncb1645 |
0.402 |
|
| 2007 |
Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells Molecular Cancer Therapeutics. 6: 2515-2524. PMID 17876048 DOI: 10.1158/1535-7163.Mct-06-0761 |
0.416 |
|
| 2007 |
Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4882-90. PMID 17699868 DOI: 10.1158/1078-0432.Ccr-06-3093 |
0.379 |
|
| 2007 |
Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Molecular Cancer Therapeutics. 6: 1400-5. PMID 17431118 DOI: 10.1158/1535-7163.Mct-06-0446 |
0.478 |
|
| 2007 |
Fiskus W, Bhalla KN. Histone Deacetylase Inhibitors and Chronic Myeloid Leukemia Oral History Review. 40. DOI: 10.17925/Ohr.2007.00.2.40 |
0.356 |
|
| 2007 |
Jabbour E, le Coutre P, Baccarani M, Bhalla K, Ossenkoppele GJ, Hochhaus A, Gattermann N, Haque A, Weitzman A, Kantarjian H. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) Journal of Clinical Oncology. 25: 7039-7039. DOI: 10.1200/Jco.2007.25.18_Suppl.7039 |
0.33 |
|
| 2007 |
Giles FJ, Coutre Pl, Bhalla K, Rosti G, Ossenkoppele G, Alimena G, Weitzman A, Zheng M, Kantarjian H. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib Journal of Clinical Oncology. 25: 7038-7038. DOI: 10.1200/Jco.2007.25.18_Suppl.7038 |
0.336 |
|
| 2007 |
Bhalla KN, Fiskus W, Herger B, Rao R, Ustun C, Jillella A, Atadja P. Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90 Journal of Clinical Oncology. 25: 10501-10501. DOI: 10.1200/Jco.2007.25.18_Suppl.10501 |
0.498 |
|
| 2007 |
Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Wang Y, Mandawat A, Lee P, Atadja P, Bhalla K. Molecular Characterization and Drug-Sensitivity of Pan Histone Deacetylase Inhibitor Resistant Human Acute Myeloid Leukemia Cells. Blood. 110: 807-807. DOI: 10.1182/Blood.V110.11.807.807 |
0.494 |
|
| 2007 |
Kantarjian HM, Hochhaus A, Cortes J, Martinelli G, Bhalla KN, Giles FJ, Ossenkoppele G, Gattermann N, Haque A, Gallagher N, Baccarani M, Coutre Pl. Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. Blood. 110: 735-735. DOI: 10.1182/Blood.V110.11.735.735 |
0.345 |
|
| 2007 |
Mandawat A, Fiskus W, Jakubowski A, Rao R, Wang Z, Fernandez P, Wang Y, Lee P, Jillela A, Atadja P, Fujii N, Peiper SC, Bhalla K. Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists. Blood. 110: 537-537. DOI: 10.1182/Blood.V110.11.537.537 |
0.515 |
|
| 2007 |
Cerchietti L, Figueroa ME, Meyers D, Cole PA, Bhalla K, Melnick A. Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL. Blood. 110: 523-523. DOI: 10.1182/Blood.V110.11.523.523 |
0.483 |
|
| 2007 |
Wang H, Cheng F, Noyes D, Wright K, Mohapatra S, Tao J, Schell M, Sebti S, Smith M, Bhalla K, Pinilla J, Dessureault S, Celis D, Sotomayor EM, Sotomayor IbEM. Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies. Blood. 110: 2315-2315. DOI: 10.1182/Blood.V110.11.2315.2315 |
0.428 |
|
| 2007 |
Rao R, Fiskus W, Joshi R, Chen J, Fernandez P, Wang Y, Lee P, Jillella A, Tao J, Atadja P, Sotomayor E, Bhalla K. Targeting Histone Deacetylases and Unfolded Protein Mediated Endoplasmic Reticulum (ER) Stress as a Strategy Against Human Mantle Cell Lymphoma. Blood. 110: 1378-1378. DOI: 10.1182/Blood.V110.11.1378.1378 |
0.504 |
|
| 2007 |
Wang H, Cheng F, Nguyen D, Suarez I, Wright K, Atadja A, Seto E, Bhalla K, Villagra A, Sotomayor E. A Novel Role of Histone Deacetylase 11 (HDAC11) in the Regulation of IL-10 Production and Immune Tolerance Mediated by Antigen-Presenting Cells. Blood. 110: 1330-1330. DOI: 10.1182/Blood.V110.11.1330.1330 |
0.36 |
|
| 2007 |
Cortes J, Jabbour E, Hochhaus A, le Coutre P, Baccarani M, Bhalla KN, Ossenkoppele G, Gattermann N, Haque A, Gallagher N, Giles F, Kantarjian HM. Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). Blood. 110: 1040-1040. DOI: 10.1182/Blood.V110.11.1040.1040 |
0.344 |
|
| 2007 |
Giles FJ, Coutre Pl, Bhalla KN, Ossenkoppele G, Alimena G, Haque A, Gallagher N, Kantarjian HM. Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC). Blood. 110: 1029-1029. DOI: 10.1182/Blood.V110.11.1029.1029 |
0.328 |
|
| 2006 |
Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Molecular Cancer Therapeutics. 5: 3096-104. PMID 17172412 DOI: 10.1158/1535-7163.Mct-06-0418 |
0.451 |
|
| 2006 |
Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4628-35. PMID 16899611 DOI: 10.1158/1078-0432.Ccr-06-0511 |
0.417 |
|
| 2006 |
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Research. 66: 6512-20. PMID 16818622 DOI: 10.1158/0008-5472.Can-06-0369 |
0.313 |
|
| 2006 |
Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. The New England Journal of Medicine. 354: 2542-51. PMID 16775235 DOI: 10.1056/Nejmoa055104 |
0.331 |
|
| 2006 |
Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between Extrinsic and Intrinsic Cell Death Pathways in Pancreatic Cancer: Synergistic Action of Estrogen Metabolite and Ligands of Death Receptor Family Cancer Research. 66: 4309-4318. PMID 16618756 DOI: 10.1158/0008-5472.Can-05-2657 |
0.414 |
|
| 2006 |
Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 108: 645-52. PMID 16537804 DOI: 10.1182/Blood-2005-11-4639 |
0.515 |
|
| 2006 |
Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Molecular Pharmacology. 69: 1527-33. PMID 16436588 DOI: 10.1124/Mol.105.020172 |
0.391 |
|
| 2006 |
Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV, Blagosklonny MV. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death & Differentiation. 13: 1434-1441. PMID 16311509 DOI: 10.1038/Sj.Cdd.4401812 |
0.43 |
|
| 2006 |
Fiskus W, Pranpat M, Balasis M, Atadja P, Manley P, Giles F, Bhalla K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells Journal of Clinical Oncology. 24: 6592-6592. DOI: 10.1200/Jco.2006.24.18_Suppl.6592 |
0.509 |
|
| 2006 |
Kantarjian HM, Gattermann N, O'Brien SG, Bhalla K, Hochhaus A, Cervantes F, Alland L, Ottmann O, Giles F, Coutre PL. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) Journal of Clinical Oncology. 24: 6531-6531. DOI: 10.1200/Jco.2006.24.18_Suppl.6531 |
0.352 |
|
| 2006 |
Tanaka C, Smith T, Kantarjian H, Giles F, Ottmann O, Bhalla K, Grouss K, Sethuraman V, Thomas K, Schran H. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL) Journal of Clinical Oncology. 24: 3095-3095. DOI: 10.1200/Jco.2006.24.18_Suppl.3095 |
0.349 |
|
| 2006 |
Bhalla KN, Bali P, Balasis M, Fiskus W, Pranpat M, Rocha K, Rao RM, Kumaraswamy S, Atadja P. Inhibition of histone deacetylase (HDAC) 6 sensitizes human leukemia and breast cancer cells to antagonists of heat shock protein (hsp) 90 and/or bortezomib (BZ) Journal of Clinical Oncology. 24: 13039-13039. DOI: 10.1200/Jco.2006.24.18_Suppl.13039 |
0.466 |
|
| 2006 |
Rao R, Fiskus W, Herger B, Atadja P, Bhalla K. Inhibition of Histone Deacetylase (HDAC) 6 and/or Heat Shock Protein (HSP) 90: A Strategy To Abrogate Multi-Level Protective Responses to Misfolded Proteins Induced by Proteasome Inhibitors in Human Leukemia Cells. Blood. 108: 257-257. DOI: 10.1182/Blood.V108.11.257.257 |
0.482 |
|
| 2006 |
Fiskus W, Herger B, Rao R, Atadja P, Bhalla K. Hydroxamate Pan-HDAC Inhibitor LBH589 Depletes EZH2 and DNMT1, Partly through hsp90 Inhibition and Its Chaperone Association with DNMT1. Blood. 108: 2233-2233. DOI: 10.1182/Blood.V108.11.2233.2233 |
0.456 |
|
| 2006 |
Herger B, Fiskus W, Rao R, Bhalla K. Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML. Blood. 108: 1905-1905. DOI: 10.1182/Blood.V108.11.1905.1905 |
0.508 |
|
| 2005 |
Fischer T, Patnaik A, Bhalla K, Beck J, Morganroth J, Laird GH, Sharma S, Scott JW, Dugan M, Giles F. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3106. PMID 27946070 DOI: 10.1200/Jco.2005.23.16_Suppl.3106 |
0.325 |
|
| 2005 |
Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Research. 65: 10536-44. PMID 16288046 DOI: 10.1158/0008-5472.Can-05-1799 |
0.324 |
|
| 2005 |
Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics. 4: 1311-9. PMID 16170022 DOI: 10.1158/1535-7163.Mct-04-0287 |
0.326 |
|
| 2005 |
Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6382-9. PMID 16144943 DOI: 10.1158/1078-0432.Ccr-05-0344 |
0.396 |
|
| 2005 |
Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. The Journal of Biological Chemistry. 280: 26729-34. PMID 15937340 DOI: 10.1074/Jbc.C500186200 |
0.446 |
|
| 2005 |
Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3971-93. PMID 15897549 DOI: 10.1200/Jco.2005.16.600 |
0.386 |
|
| 2005 |
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 105: 1768-76. PMID 15514006 DOI: 10.1182/Blood-2004-09-3413 |
0.527 |
|
| 2005 |
Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 105: 1135-43. PMID 15454486 DOI: 10.1182/Blood-2004-01-0027 |
0.349 |
|
| 2005 |
Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood. 105: 1246-55. PMID 15388581 DOI: 10.1182/Blood-2004-05-2041 |
0.352 |
|
| 2005 |
Bhalla KN, Bali P, Pranpat M, Fiskus W, Guo F, Sigua C, Swaby R. Molecular mechanisms of underlying synergistic effect of combinations of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) with docetaxel and trastuzumab against human breast cancer cells Journal of Clinical Oncology. 23: 560-560. DOI: 10.1200/Jco.2005.23.16_Suppl.560 |
0.46 |
|
| 2005 |
Ma W, Kantarjian H, Jilani I, Gorre M, Ottmann, Bhalla K, Giles F, Albitar M. Discrepancy in Detecting Bcr-Abl Kinase Domain Mutations between Cells from Bone Marrow and Cells from Peripheral Blood, and Greater Concordance between Bone Marrow Cells and Plasma Free RNA. Blood. 106: 4849-4849. DOI: 10.1182/Blood.V106.11.4849.4849 |
0.329 |
|
| 2005 |
Fiskus W, Pranpat M, Bali P, Kumaraswamy S, Boyapalle S, Rocha K, Balasis M, Atadja P, Bhalla K. Histone Deacetylase Inhibitors LBH589 and LAQ824 Deplete Ezh2 and Associated Polycomb Repressive Complex 2/3 Proteins Resulting in Downregulation of HOXA9 and MEIS1 Expression in Human Acute Leukemia Cells. Blood. 106: 2482-2482. DOI: 10.1182/Blood.V106.11.2482.2482 |
0.498 |
|
| 2005 |
Wang H, Cheng F, Horna P, Suarez I, Wu J, Atadja A, Seto E, Wright K, Bhalla K, Sotomayor E. Treatment of Antigen-Presenting Cells with Histone Deacetylase Inhibitors Represents a Novel Strategy To Overcome CD4+ T-Cell Tolerance: Divergent Effects on the IL10 and IL-12 Promoter. Blood. 106: 2392-2392. DOI: 10.1182/Blood.V106.11.2392.2392 |
0.369 |
|
| 2005 |
Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O’Brien S, Giles F, Albitar M. Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia. Blood. 106: 2006-2006. DOI: 10.1182/Blood.V106.11.2006.2006 |
0.356 |
|
| 2005 |
Gorre M, Kantarjian H, Jilani I, Cortes J, Salvado A, Rae P, Alland L, Dugan M, Ottmann O, Bhalla K, Giles F, Albitar M. Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways. Blood. 106: 2001-2001. DOI: 10.1182/Blood.V106.11.2001.2001 |
0.364 |
|
| 2004 |
Bhalla KN, George P, Gutti R, Bali P, Tao J, Guo F, Sigua C, Li Y, Cohen P, Atadja P. A combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant FLT-3 tyrosine kinase. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6541. PMID 28016935 DOI: 10.1200/Jco.2004.22.14_Suppl.6541 |
0.479 |
|
| 2004 |
Bhalla K, List A. Histone deacetylase inhibitors in myelodysplastic syndrome. Best Practice & Research. Clinical Haematology. 17: 595-611. PMID 15494297 DOI: 10.1016/J.Beha.2004.08.011 |
0.427 |
|
| 2004 |
Staley CA, Harris WB, Landry J, Small W, Kooby D, Gillespie TW, Meyers M, Bhalla KN. Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies. Surgical Oncology Clinics of North America. 13: 697-709, x. PMID 15350943 DOI: 10.1016/J.Soc.2004.06.011 |
0.318 |
|
| 2004 |
Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. Journal of Immunological Methods. 292: 59-71. PMID 15350512 DOI: 10.1016/J.Jim.2004.06.003 |
0.32 |
|
| 2004 |
Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4991-7. PMID 15297399 DOI: 10.1158/1078-0432.CCR-04-0210 |
0.36 |
|
| 2004 |
Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. The Journal of Biological Chemistry. 279: 39431-7. PMID 15262986 DOI: 10.1074/Jbc.M401530200 |
0.459 |
|
| 2004 |
Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Foundation Symposium. 259: 249-66; discussion 2. PMID 15171259 |
0.399 |
|
| 2004 |
George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Research. 64: 3645-52. PMID 15150124 DOI: 10.1158/0008-5472.CAN-04-0006 |
0.403 |
|
| 2004 |
Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Research. 64: 2580-9. PMID 15059915 DOI: 10.1158/0008-5472.Can-03-2629 |
0.442 |
|
| 2004 |
Bali P, Fiskus W, Guo F, Annavarapu S, Sigua C, Sondarva G, Mouttaki A, Atadja P, Manley P, Bhalla KN. Molecular Characterization of Human CML Cells with Resistance to the Heat Shock Protein (hsp) 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin (17-AAG). Blood. 104: 1980-1980. DOI: 10.1182/Blood.V104.11.1980.1980 |
0.471 |
|
| 2004 |
Scuto A, Annavarapu S, Bali P, McCullers M, Fiskus W, Mouttaki A, Guo F, Sigua C, Sondarva G, Atadja P, Manley P, Bhalla KN. Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells. Blood. 104: 1977-1977. DOI: 10.1182/Blood.V104.11.1977.1977 |
0.537 |
|
| 2004 |
Guo F, Sigua C, Bali P, Fiskus W, Sondarva G, Annavarapu S, Mouttaki A, Atadja P, Bhalla KN. Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors. Blood. 104: 1171-1171. DOI: 10.1182/Blood.V104.11.1171.1171 |
0.515 |
|
| 2004 |
Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824 Novartis Foundation Symposium. 259: 249-268. DOI: 10.1002/0470862637.Ch19 |
0.496 |
|
| 2003 |
Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 22: 9075-86. PMID 14663486 DOI: 10.1038/Sj.Onc.1207233 |
0.423 |
|
| 2003 |
Nimmanapalli R, Bali P, O'Bryan E, Fuino L, Guo F, Wu J, Houghton P, Bhalla K. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Research. 63: 7950-8. PMID 14633726 |
0.368 |
|
| 2003 |
Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular Cancer Therapeutics. 2: 971-84. PMID 14578462 |
0.394 |
|
| 2003 |
Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Research. 63: 5126-35. PMID 12941844 |
0.451 |
|
| 2003 |
Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. The Journal of Biological Chemistry. 278: 42992-3000. PMID 12933816 DOI: 10.1074/Jbc.M306295200 |
0.376 |
|
| 2003 |
Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecologic Oncology. 89: 37-47. PMID 12694652 DOI: 10.1016/S0090-8258(03)00006-4 |
0.389 |
|
| 2003 |
Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood. 102: 269-75. PMID 12623837 DOI: 10.1182/Blood-2002-12-3718 |
0.463 |
|
| 2003 |
Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Research. 63: 93-9. PMID 12517783 |
0.354 |
|
| 2002 |
Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, ... Bhalla K, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 21: 8804-16. PMID 12483533 DOI: 10.1038/Sj.Onc.1206028 |
0.425 |
|
| 2002 |
Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene. 21: 8584-8590. PMID 12476305 DOI: 10.1038/Sj.Onc.1206086 |
0.433 |
|
| 2002 |
Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 101: 3236-9. PMID 12446442 DOI: 10.1182/blood-2002-08-2675 |
0.428 |
|
| 2002 |
Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Research. 62: 5761-9. PMID 12384536 |
0.352 |
|
| 2002 |
Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla K, Jove R, Wu J. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia. 16: 1589-1595. PMID 12200668 DOI: 10.1038/Sj.Leu.2402678 |
0.399 |
|
| 2002 |
Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-κB activation and IκBα phosphorylation: Relationship with down-regulation of TNF receptors Journal of Biological Chemistry. 277: 30622-30628. PMID 12060665 DOI: 10.1074/Jbc.M204748200 |
0.405 |
|
| 2002 |
Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O'Bryan E, Fumero C, Wang HG, Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood. 99: 3419-26. PMID 11964312 DOI: 10.1182/Blood.V99.9.3419 |
0.373 |
|
| 2002 |
Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Research. 62: 466-71. PMID 11809697 |
0.333 |
|
| 2001 |
Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 15: 772-8. PMID 11368438 DOI: 10.1038/Sj.Leu.2402104 |
0.363 |
|
| 2000 |
Cai J, Zheng T, Masood R, Smith DL, Hinton DR, Kim CN, Fang G, Bhalla K, Gill PS. Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. Sarcoma. 4: 37-45. PMID 18521433 DOI: 10.1155/S1357714X00000074 |
0.42 |
|
| 2000 |
Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway Journal of Virology. 74: 1513-1523. PMID 10627563 DOI: 10.1128/Jvi.74.3.1513-1523.2000 |
0.376 |
|
| 2000 |
Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs Blood. 96: 2246-2253. DOI: 10.1182/Blood.V96.6.2246 |
0.477 |
|
| 2000 |
Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L–induced apoptosis of human acute leukemia cells Blood. 96: 3900-3906. DOI: 10.1182/Blood.V96.12.3900 |
0.428 |
|
| 2000 |
Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL Blood. 95: 1014-1022. DOI: 10.1182/Blood.V95.3.1014.003K04_1014_1022 |
0.483 |
|
| 1999 |
Kim CN, Bhalla K, Kreitman RJ, Willingham MC, Hall P, Tagge EP, Jia T, Frankel AE. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leukemia Research. 23: 527-38. PMID 10374846 DOI: 10.1016/S0145-2126(99)00039-9 |
0.424 |
|
| 1999 |
Burri SH, Kim CN, Fang G, Chang BS, Perkins C, Harris W, Davis LW, Thompson CB, Bhalla KN. 'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosis. International Journal of Radiation Oncology, Biology, Physics. 43: 423-30. PMID 10030271 DOI: 10.1016/S0360-3016(98)00385-X |
0.439 |
|
| 1999 |
Han Z, Bhalla K, Pantazis P, Hendrickson EA, Wyche JH. Cif (Cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid. Molecular and Cellular Biology. 19: 1381-9. PMID 9891071 DOI: 10.1128/Mcb.19.2.1381 |
0.393 |
|
| 1998 |
Ibrado AM, Kim CN, Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia. 12: 1930-1936. PMID 9844922 DOI: 10.1038/Sj.Leu.2401218 |
0.403 |
|
| 1998 |
Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling Embo Journal. 17: 6888-6902. PMID 9843495 DOI: 10.1093/Emboj/17.23.6888 |
0.443 |
|
| 1997 |
Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Research and Treatment. 42: 73-81. PMID 9116321 DOI: 10.1023/A:1005777219997 |
0.415 |
|
| 1997 |
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (New York, N.Y.). 275: 1129-32. PMID 9027314 DOI: 10.1126/Science.275.5303.1129 |
0.332 |
|
| 1997 |
Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11: 253-7. PMID 9009089 DOI: 10.1038/Sj.Leu.2400557 |
0.367 |
|
| 1997 |
Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the Apoptotic Response of Human Myeloid Leukemia Cells to a Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Blood. 90: 3654-3661. DOI: 10.1182/Blood.V90.9.3654 |
0.412 |
|
| 1995 |
Kumar G, Ray S, Walle T, Huang Y, Willingham M, Self S, Bhalla K. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemotherapy and Pharmacology. 36: 129-35. PMID 7767949 DOI: 10.1007/Bf00689197 |
0.315 |
|
| 1994 |
Liu Y, Bhalla K, Hill C, Priest DG. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochemical Pharmacology. 48: 1265-72. PMID 7945420 DOI: 10.1016/0006-2952(94)90164-3 |
0.427 |
|
| 1994 |
Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, Bullock G, Bhalla K. 1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemotherapy and Pharmacology. 34: 365-71. PMID 7915211 DOI: 10.1007/Bf00685559 |
0.308 |
|
| 1994 |
Tang C, Huang Y, Ponnathpur VS, Ray S, Mahoney ME, Bullock G, Ibrado AM, Bhalla K. Combined antileukemic activity of pIXY 321 and Ara-C against human acute myeloid leukemia cells. Leukemia & Lymphoma. 15: 445-51. PMID 7874002 DOI: 10.3109/10428199409049748 |
0.375 |
|
| 1993 |
Bhalla K, Tourkina E, Huang Y, Tang C, Mahoney ME, Ibrado AM. Effect of hemopoietic growth factors G-CSF and pIXY 321 on the activity of high dose Ara-C in human myeloid leukemia cells. Leukemia & Lymphoma. 10: 123-31. PMID 7683227 DOI: 10.3109/10428199309149124 |
0.435 |
|
| 1993 |
Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 82: 3133-3140. DOI: 10.1182/Blood.V82.10.3133.3133 |
0.477 |
|
| 1992 |
Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M, Singh S. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecologic Oncology. 45: 32-9. PMID 1601333 DOI: 10.1016/0090-8258(92)90487-4 |
0.385 |
|
| 1992 |
Bhalla K, Tang C, Ibrado A, Grant S, Tourkina E, Holladay C, Hughes M, Mahoney M, Huang Y. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells Blood. 80: 2883-2890. DOI: 10.1182/Blood.V80.11.2883.Bloodjournal80112883 |
0.453 |
|
| 1991 |
Grant S, Bhalla K, McCrady C. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Leukemia Research. 15: 205-13. PMID 2030601 DOI: 10.1016/0145-2126(91)90122-A |
0.383 |
|
| 1991 |
Bhalla K, Swerdlow P, Grant S. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells Blood. 78: 2937-2944. DOI: 10.1182/Blood.V78.11.2937.2937 |
0.353 |
|
| 1991 |
Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado A, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony- stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts Blood. 78: 2674-2679. DOI: 10.1182/Blood.V78.10.2674.Bloodjournal78102674 |
0.335 |
|
| 1990 |
Bhalla KN, Gongrong L, Grant S, Cole JT, MacLaughlin WW, Volsky DJ. The effect in vitro of 2′-deoxycytidine on the metabolism and cytotoxicity of 2′,3′-dideoxycytidine Aids. 4: 427-431. PMID 2115341 DOI: 10.1097/00002030-199005000-00008 |
0.343 |
|
| 1986 |
Bhalla K, Cole J, MacLaughlin W, Baker M, Arlin Z, Graham G, Grant S. Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1 Blood. 68: 1136-1141. DOI: 10.1182/Blood.V68.5.1136.1136 |
0.344 |
|
| Show low-probability matches. |